Fulcrum stock maintains Overweight rating at Cantor on sickle cell drug

Cantor Fitzgerald reiterated its Overweight rating and $10 price target on Fulcrum Therapeutics (FULC), citing potential upside from its sickle cell disease treatment, pociredir, as the company approaches a key clinical data readout. Fulcrum reported a Q1 2025 net loss of $17.7 million, an improvement from $26.9 million in Q1 2024, while Leerink Partners upgraded the stock to Outperform with a $600 million peak sales estimate, driven by optimism surrounding pociredir following the withdrawal of Pfizer's Oxbryta and slow gene therapy adoption; the company's cash is expected to fund operations into 2027.

Analysis

Cantor Fitzgerald has reiterated its Overweight rating and $10.00 price target for Fulcrum Therapeutics (NASDAQ:FULC), signaling confidence in the potential of its sickle cell disease treatment, pociredir, ahead of an upcoming clinical data readout. The stock, trading at $6.36, has demonstrated significant recent momentum, appreciating 46% over the past six months. Fulcrum's market capitalization stands at $343 million, and it boasts a "GREAT" financial health score from InvestingPro, which also suggests the stock is currently undervalued, albeit with high volatility indicated by a beta of 2.42. The company's Q1 2025 financial results showed an improved net loss of $17.7 million, compared to $26.9 million in Q1 2024, driven by reductions in both Research and Development expenses (to $13.4 million from $19.8 million) and General and Administrative expenses (to $7.0 million from $10.1 million). Further bolstering the outlook, Leerink Partners upgraded FULC to Outperform, increasing gross peak sales estimates for pociredir to $600 million, citing the withdrawal of Pfizer's Oxbryta and the slow uptake of gene therapy alternatives as favorable market conditions. Fulcrum's cash reserves are anticipated to support operations into at least 2027, providing a stable runway as it advances pociredir, with data from the 12mg PIONEER trial cohort expected in early Q3 2025. Key considerations for investors revolve around the risk/benefit profile that will drive physician adoption and how the FDA might interpret clinical data for potential label expansion.

Key Decisions for Investors

• Investors should closely monitor the upcoming pociredir clinical data readout in early Q3 2025, as positive results could significantly de-risk the asset and serve as a major catalyst for the stock.
• Given analyst optimism and a financial runway into 2027, consider the stock's current valuation relative to its $10 price target and $600 million peak sales potential, while remaining cognizant of the high volatility (beta 2.42) typical of clinical-stage biotech companies.
• Assess the competitive landscape, particularly the implications of Pfizer's Oxbryta withdrawal and slow gene therapy adoption, which may enhance pociredir's market opportunity if clinical data is favorable.